Competitive Acquisition Vendors Should Pay Drug Returns – CMS Doctor Panel
Executive Summary
Competitive acquisition program vendors should be responsible for the cost of wasted or returned products, the Centers for Medicare & Medicaid Services Practicing Physician Advisory Council recommended to the agency
You may also be interested in...
CMS Could Award Up To 250 Part B Rx Contracts Under Bidding Program
Medicare could award anywhere from five to 250 separate Part B drug vendor contracts under the competitive acquisition program depending on how the Centers for Medicare & Medicaid Services ends up defining bidding areas
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials